【摘 要】
：
Objective:To confirm the efficacy and safety of fifth new drug Pai-Neng-Da capsule in the treatment of Leukopenia with unknown causes.Method: From March 2013 to June 2015,96 cases of patients with unk
【机 构】
：
The First Affiliated Hospital of Zhejiang Chinese Medical University
【出 处】
：
全国民族医、中医血液病学术研讨会暨青年学术论坛
论文部分内容阅读
Objective:To confirm the efficacy and safety of fifth new drug Pai-Neng-Da capsule in the treatment of Leukopenia with unknown causes.Method: From March 2013 to June 2015,96 cases of patients with unknown causes of Leukopenia were treated with Pai-Neng-Da capsule, Leucogen and combination of the two drugs.The leukocyte count, TCMSyndrome and improvement of life quality of three groups before and after treatment were observed.Liver and kidney function, infection, gastrointestinal reactions and other adverse reactions in the course of treatment were also monitored.Result: Regarding to leukocyte count, the total effective rates were 51.6%, 46.7%and 74.3%in Pai-Neng-Da capsule group, Leucogen group and the combination group.There were no significant differences (P>0.05)in the efficacy between Pai-Neng-Da capsule group and Leucogen group,while the combination group preceded to that of the single drug groups, with significant difference(P<0.05).Regarding to TCMSyndrome, the total effective rates in Pai-Neng-Da, Leucogen and the combination group were 87.1%, 46.7%and 94.3%, respectively.There were statistically significant differences between Pai-Neng-Da group and Leucogen group(P<0.05),while no significant differences between Pai-Neng-Da group and the combination(P>0.05).SF-36 score was significantly different in each group before and after treatment(P< 0.05).Comparison among groups:There were significant differences in the improvement of SF-36 score between PaiNeng-Da capsule group and Leucogen group (P<0.05), while no significant differences between Pai-Neng-Da and the combination group(P>0.05).All cases had complete test and no obvious adverse reaction was found.Conclusion:The effect of fifth new drug Pai-Neng-Da capsule in treatment of Leukopenia with unknown causes is similar to that of Leucogen.The combination can further improve efficacy with no obvious adverse reactions.
其他文献
Immune thrombocytopenia(ITP), also known as idiopathic thrombocytopenic purpura, is anautoimmune disease characterized by low platelet count and increased bleeding tendency.Currently, glucocorticoid a
目的：使用数据挖掘方法对全国名老中医黄振翘教授治疗原发免疫性血小板减少症的大量验案进行分析，总结黄教授的用药规律，传承黄教授的学术思想.方法：将大量病案经过预处理后建立标准化的病案数据库，共纳入357诊次；通过Microsoft Office Excel 2003、SPSS 18.0、IBMSPSS Modeler14.1等软件，分别运用频数分析、系统聚类分析以及关联分析Apriori算法进行数据
目的：研究分析在我中心诊治的SPTCL患者的临床及病理特征.方法：总结了从2010年1月至2015年12月在我中心诊治的6例SPTCL患者的临床及病理特征.结果：6例SPTCL患者中,男女比例为2：1.不同于欧美之前报道过的平均发病年龄39岁,6例患者的平均诊断年龄为29岁(2～53岁),其中4例(67％)的病人低于30岁.起病部位包括腹股沟、臀部、上肢以及下肢,5例(83％)病人表现为皮下的硬结
目的：分析PET/CT在多发性骨髓瘤(MM)预后生存中的作用.方法：对68例初治MM患者入院后均完善血液学检查,治疗前均行PET/CT检查.测量伴髓外病变的25例患者的髓外病变区域最大标准摄取值(SUVmax),所有患者均测量骨病变区的最大SUVmax.并统计PET/CT上骨破坏数量和(或)累及髓外病变数量.通过随访获得总生存期(OS)及无进展生存期(PFS).将PET/CT结合实验室指标进行预后
Multiple myeloma(MM), which arises from the uncontrolled proliferation of terminally differentiated B cells or plasma cells, is the second most commonly diagnosed hematologic malignancy in the United
The oncogenic microRNA miR-21 contributes to the pathogenesis of multiple myeloma(MM).Ibrutinib (also referred to as PCI-32765), an inhibitor of Brutons tyrosine kinase(BTK), has been approved by the
IRF8 is a transcription factor with a critical role in B lymphocyte development and biological functions.In our previous work, we have shown that IRF8 plays a significant role in the growth of human d
目的：分析31例获得性21三体(+21)异常急性髓系白血病(AML)的临床特征及预后意义.方法：采用骨髓直接法和(或)培养法制备染色体标本,采用R显带技术进行核型分析,并对获得性+21患者的临床特征、化疗疗效及生存状况进行分析.结果：接受细胞遗传学检查的3329例初发AML患者中检出+21异常31例,占全部的0.93％,其中单纯+21异常16例,占全部的0.48％.+21异常AML的分型中以M5b
FLT3-ITD and DNMT3A R882 mutations are both independent factors for poor prognosis of acute my eloid leukemia(AML).Allogeneic hematopoietic stem cell transplantation (allo-HSCT)has been confirmed to i
Background: HLS5 belongs to the RBCC (Ring-finger, B-box, coiled-coil)family, a family of tumor suppressive genes including Pm, Tif1-α, Heff and Rfp, it has been reported to regulate erythroid differe